A rational pharmacologic approach toward a biologically meaningful subtype of autism spectrum disorder
Open Access
- 1 January 2021
- journal article
- editorial
- Published by Elsevier BV in Jornal de Pediatria
- Vol. 97 (1), 1-3
- https://doi.org/10.1016/j.jped.2020.05.001
Abstract
No abstract availableFunding Information
- Nancy Lurie Marks Family Foundation
- Robert and Donna Landreth Family Fund
This publication has 16 references indexed in Scilit:
- Pioglitazone abolishes autistic-like behaviors via the IL-6 pathwayPLOS ONE, 2018
- Toward an immune-mediated subtype of autism spectrum disorderBrain Research, 2015
- Interleukin-6-induced S100B secretion is inhibited by haloperidol and risperidoneProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2013
- Risperidone normalizes increased inflammatory parameters and restores anti-inflammatory pathways in a model of neuroinflammationInternational Journal of Neuropsychopharmacology, 2013
- Peripheral and central inflammation in autism spectrum disordersMolecular and Cellular Neuroscience, 2012
- Immune Dysfunction in Autism: A Pathway to TreatmentNeurotherapeutics, 2010
- Autismo infantil: tradução e validação da Childhood Autism Rating Scale para uso no BrasilJornal de Pediatria, 2008
- Childhood autism: translation and validation of the Childhood Autism Rating Scale for use in BrazilJornal de Pediatria, 2008
- Effect of pioglitazone treatment on behavioral symptoms in autistic childrenJournal of Neuroinflammation, 2007
- Peroxisome Proliferator-activated Receptor γ Thiazolidinedione Agonists Increase Glucose Metabolism in AstrocytesJournal of Biological Chemistry, 2003